Medicenna Therapeutics Corp. (TSE:MDNA – Get Rating)’s share price reached a new 52-week low during trading on Monday . The company traded as low as C$1.04 and last traded at C$1.10, with a volume of 16122 shares. The stock had previously closed at C$1.22.
A number of equities analysts have recently commented on the company. Brookline Capital Acquisition lifted their price objective on Medicenna Therapeutics to C$14.00 and gave the stock a “buy” rating in a research note on Wednesday, April 13th. Maxim Group assumed coverage on Medicenna Therapeutics in a research note on Tuesday, May 3rd. They set a “buy” rating and a C$4.00 price target on the stock.
The company has a debt-to-equity ratio of 0.06, a current ratio of 11.07 and a quick ratio of 10.21. The stock has a market capitalization of C$58.91 million and a P/E ratio of -2.59. The firm has a 50 day moving average of C$1.37 and a 200-day moving average of C$1.79.
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors.
- The Analysts Rip The Seams Out Of Stitch Fix
- Atlassian Stock: Taking Another Look
- Doximity Stock is an Interesting Healthcare Play
- Where Are Interest Rates Going This Year? A Lot Higher
- SunPower Stock is a Value Solar Play
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.